Chronopharmacokinetics and chronopharmacodynamics of dextromethamphetamine in man

Journal of Clinical Pharmacology

Volumn 36, Issue 11, 1996, Pages 1051-1063

  Shappell, Scott A ^a   Kearns, Gregory L ^b,c   Valentine, Jimmie L ^b,c   Neri, David F ^d   DeJohn, Charles A ^e  

^a Naval Air Force   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c ARKANSAS CHILDREN S HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e CIVIL AEROSPACE MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; DEXAMPHETAMINE;

ADULT; ARTICLE; BRAIN DEPTH STIMULATION; CENTRAL NERVOUS SYSTEM FUNCTION; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG TRANSFORMATION; FATIGUE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PATTERN RECOGNITION;

EID: 0030458724     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009603601109     Document Type: Article

References (66)

1. Neri DF, Shappell SA: The effect of combat on the work/rest schedules and fatigue of naval aviators during Operation Desert Shield/Storm. Mil Psychol 1984;6:141-162.
2. Shappell SA, Neri DF: The effect of combat on aircrew subjective readiness during Operation Desert Shield/Storm, Int J Aerospace Psychol 1993;3:231-252.
3. Shappell SA, Neri DF, Dejohn CA: Simulated sustained flight operations and performance. II. Effects of dextromethamphetamine. Mil Psychol 1992;4:267-287.
4. Weiner N: Amphetamine. In, Gilman AG, Goodman LS, Rall TW, Murad F (eds.): The Pharmacological Basis of Therapeutics. New York: MacMillan, 1985;145-180.
5. Ridley RM, Baker HF, Crow TJ: Behavioral effects of amphetamines and related stimulants: the importance of species differences as demonstrated by a study in the marmoset. In, Caldwell J (ed.): Amphetamines and Related Stimulants: Chemical, Biological, Clinical, and Sociological Aspects. Boca Raton, FL: CRC Press, 1980;97-116.
6. Vree TB, Henderson PT: Pharmacokinetics of amphetamines: in vivo and in vitro studies of factors governing their elimination. In, Caldwell J (ed.): Amphetamines and Related Stimulants: Chemical, Biological, Clinical, and Sociological Aspects. Boca Raton, FL: CRC Press, 1980;47-68.
7. Seashore RH, Ivy AC: The effects of analeptic drugs in relieving fatigue. Psychol Monogr 1953;67:1-16.
8. Silverstone T, Wells B: Clinical psychopharmacology of amphetamines and related compounds. In, Caldwell J (ed.): Amphetamines and Related Stimulants: Chemical, Biological, Clinical, and Sociological Aspects. Boca Raton, FL: CRC Press, 1980; 147-160.
9. Weiss B: Enhancement of performance by amphetamine-like drugs. In, Sjoqvist F, Tottie M (eds.): Abuse of Central Stimulants. Stockholm, Sweden: Almquist & Wiksell, 1985;31-60.
10. Ando K: Profile of drug effects on temporally spaced responding in rats. Pharmacol Biochem Behav 1975;3:833-841.
11. Calhoun WH, Jones EA: Methamphetamine's effect on repeated acquisitions with serial discrimination reversals. Psychopharmacologia 1974;39:303-308.
12. Estler C, Gabrys MC: Swimming capacity of mice after prolonged treatment with psychostimulants. II. Effect of methamphetamine on swimming performance and availability of metabolic substrates. Psychopharmacology 1979;60:173-176.
13. Evans HL, Ghiselli WB, Patton RA: Diurnal rhythm in behavioral effects of methamphetamine, p-chloromethamphetamine and scopolamine. J Pharmacol Exp Ther 1973;186:10-17.
14. Franken RE, Strain A: Effect of increased arousal on response to stimulus change in a complex maze. Percep Mot Skills 1974,39:1076-1078.
15. Hughes R, Greig AM: Effects of caffeine, methamphetamine and methylphenidate on reactions to novelty and activity in rats. Neuropharmacology 1976;15:673-676.
16. Jakubczak LF, Gomer FE: Effects of food deprivation and initial levels on a wheel-running response to methamphetamine. Bull Psychonomic Soc 1973;1:343-345.
17. Kuribara H, Todokoro S: Circadian variation in methamphetamine- and apomorphine-induced increase in ambulatory activity in mice. Pharmacol Biochem Behav 1982;17:1251-1256.
18. Kuribara H, Todokoro S: Circadian variation in susceptibility to methamphetamine after repeated administration in mice. Pharmacol Biochem Behav 1984;20:247-250.
19. Maricq AV, Roberts S, Church RM: Methamphetamine and time estimation. J Exp Psychol Anim Behav 1981;7:18-30.
20. Meck WH: Selective adjustment of the speed of internal clock and memory processes. J Exp Psychol Anim Behav 1983;9:171-201.
21. Meck WH, Church RM: A mode control model of counting and timing processes. J Exp Psychol Anim Behav 1983;9:320-334.
22. Ando K, Johanson CE, Schuster CR: Effects of dopaminergic agents on eye tracking before and after repeated methamphetamine. Pharmacol Biochem Behav 1986;24:693-699.
23. Crowley TJ, Stynes A, Hydinger M, Kaufman I: Ethanol, methamphetamine, pentobarbital, morphine, and monkey social behavior. Arch Gen Psychiatry 1974;31:829-838.
24. Hienz RD, Lukas SE, Brady JV: Effects of d-methamphetamine on auditory and visual reaction times and detection thresholds in the baboon. Psychopharmacology 1985;85:476-482.
25. Foltz EE, Ivy AC, Barborka CJ: The influence of amphetamine (benzedrine) sulfate, d-desoxyephedrine hydrochloride (pervitin) and caffeine upon work output and recovery when rapidly exhausting work is done by trained subjects. J Lab Clin Med 1943;28:603-605.
26. Knoefel PK: The influence of phenisopropyl amine and phenisopropyl methyl amine on work output (letter). Fed Proc 1943;2:83.
27. Lehman G, Straub H, Szakall A: Pervitin als leistungssteigerndes Mittel. Arbeitsphysiologie 1939;10:680-690.
28. del-Porto J, Cunha J, Carlini E: Influencia da privacao de sono sobre os efeitos de drogas dopaminergicas em voluntarios (The influence of sleep deprivation on the effects of dopaminergic drugs in volunteers). J Brasileiro de Psiquiatria 1985;34:371-376.
29. Graf O: Increase of efficiency by means of pharmaceutics (stimulants). In, German Aviation Medicine, World War II. Volume 2. Washington, DC: United States Government Printing Office, 1950;1080-1103.
30. Mewaldt SP, Ghoneim MM: The effects and interactions of scopolamine, physostigmine and methamphetamine on human memory. Pharmacol Biochem Behav 1979;10:205-210.
31. Mohs RC, Tinklenberg JR, Roth WT, Kopell BS: Methamphetamine and diphenhydramine effects on the rate of cognitive processing. Psychopharmacology 1978;59:13-19.
32. Kohl RL, Calkins DS, Mandell AJ: Arousal and stability: the effects of five new sympathomimetic drugs suggest a new principle for the prevention of space motion sickness. Aviat Space Environ Med 1986;57:137-143.
33. Kopell BS, Wittner WK, Lunde DT, Wolcott LJ, Tinklenberg JR: The effects of methamphetamine and secobarbital on the contingent negative variation amplitude. Psychopharmacologia 1974;34:55-62.
34. Checkley S: A new distinction between the euphoric and the antidepressant effects of methylamphetamine. Br J Psychiatry 1978;133:416-423.
35. Kiloh L, Neilson M, Andrews G: Response of depressed patients to methylamphetamine. Br J Psychiatry 1974;125:496-499.
36. Martin WR, Sloan JW, Sapira JD, Jasinski DR: Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1970;12:245-258.
37. Mayfield DG: The effect of intravenous methamphetamine on mood. Int J Addict 1973;8:565-568.
38. Mendelson J, Jones RT, Upton R, Jacob P III: Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther 1995;57:559-68.
39. Chan P, Chen JH, Lee MH, Deng JF: Fatal and nonfatal methamphetamine intoxication in the intensive care unit. J Toxicol Clin Toxicol 1994;32:147-155.
40. Jacobs LJ: Reversible dilated cardiomyopathy induced by methamphetamine. Clin Cardiol 1989;12:725-727.
41. Katsumata S, Sato K, Kashiwade H, Yamanami S, Zhou H, Yonemura I, Nakajima H, Hasekura H: Sudden death due presumably to internal use of methamphetamine. Forensic Sci Int 1993;62:209-215.
42. Kojima T, Une I, Yashiki M, Noda J, Sakai K, Yamamoto K: A fatal methamphetamine poisoning associated with hyperpyrexia. Forensic Sci Int 1984;24:87-93.
43. Bailey DN, Shaw RF: Cocaine- and methamphetamine-related deaths in San Diego County (1987). J Forensic Sci 1989;34:407-422.
44. Lamb RJ, Henningfield JE: Human d-amphetamine drug discrimination: methamphetamine and hydromorphone. J Exp Anal Behav 1994;61:169-180.
45. Jaffe JH: Drug addiction and drug abuse. In, Gilman AG, Goodman LS, Rall TW, Murad F (eds.): The Pharmacological Basis of Therapeutics. New York: MacMillian, 1985;531-581.
46. Neri DF, Wiegmann D, Stanney RR, Shappell SA, McCardie A, McKay DL: The effects of tyrosine on cognitive performance during extended wakefulness. Aviat Space Environ Med 1995; 66:313-319.
47. Gopher D, Kahneman D: Individual differences in attention and the prediction of flight criteria. Percept Mot Skills 1971;33: 1335-1342.
48. Thorne DR, Genser SG, Sing HC, Hegge FW: The Walter Reed performance assessment battery. Neurobehavioral Toxicol Teratol 1985;7:415-418.
49. Haertzen CA, Hill HE, Belleville RE: Development of the Addiction Research Center Inventory (ARCI): selection of items that are sensitive to the effects of various drugs. Psychopharmacologia 1963;4:155-166.
50. Haertzen CA: Addiction Research Center Inventory (ARCI): development of a general drug estimation scale. J Nerv Ment Dis 1965;141:300-307.
51. Haertzen CA: Development of scales based on patterns of drug effects using the Addiction Research Center Inventory (ARCI). Psychol Rep 1966;18:163-194.
52. Hill HE, Haertzen CA, Wolbach AB Jr, Miner EJ: The Addiction Research Center Inventory: standardization of scales which evaluate subjective effects of morphine, amphetamine, pentobarbital, alcohol, LSD-25, pyrahexyl and chlorpromazine. Psychopharmacologia 1963;4:167-183.
53. Valentine JL, Kearns GL, Sparks C, Letzig LG, Valentine CR, Shappell SA, et al: GC/MS determination of amphetamine and methamphetamine in human urine for twelve hours after oral administration of dextromethamphetamine: lack of evidence supporting the established forensic guidelines for methamphetamine confirmation. J Anal Toxicol 1995;19:581-590.
54. Gomeni R, Gomeni C: AUTOMOD: a polylogarithm for an integrated analysis of linear pharmacokinetic models. Comput Biol Med 1979;9:38-48.
55. Marquardt DW: An algorithm for least-squares estimation of nonlinear parameters. J Soc Indust Appl Math 1963;11:431-441.
56. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
57. Yamaoka K, Nakagawa T, Uno T: Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 1978;6:547-558.
58. Wagner JG, Nelson E: Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug (letter). J Pharm Sci 1964;53:1392.
59. Wagner JG, Nelson E: Percent absorbed time plots derived from blood level and/or urinary excretion data. J Pharm Sci 1963;52:610-611.
60. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J: Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979;25:358-371.
61. Holford NHG, Sheiner LB: Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981;6:429-453.
62. Beckett AH, Rowland M, Turner P: Influence of urinary pH on excretion of amphetamine. Lancet 1965;1:303-304.
63. Wan SK, Matin SB, Azarnoff DL: Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH. Clin Pharmacol Ther 1978;23:585-590.
64. Cook CE, Jeffcoat AR, Sadler BM, Hill JM, Voyksner RD, Pugh DE, White WR, Perez-Reyes M: Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. Drug Metab Dispos 1992;20:856-862.
65. Vree TB, Gorgels JPMC, Muskens ATHJM, Van Rossum JM: Deuterium isotope effects in the metabolism of N-alkylsubstituted amphetamines in man. Clin Chim Acta 1971;34:333-344.
66. Lemmer J, Bruguerolle B: Chronopharmacokinetics: are they clinically relevant? Clin Pharmacokinet 1994;26:419-427.